Document 2842
 DOCN  M94A2842
 TI    Phase II study of combination of lentinan with ddI in HIV-positive
       patients.
 DT    9412
 AU    Kaneko Y; Mimura T; Guralnik M; Baker M; Goodgame J; DeMarzo C; Pierce
       D; Lang W; Gordon M; Ajinomoto Co., Inc., Tokyo, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):212 (abstract no. PB0276). Unique
       Identifier : AIDSLINE ICA10/94369733
 AB    OBJECTIVE: To assess the safety and efficacy of a combination of ddI
       (didanosine) and lentinan (an immune modulator) in HIV-positive cases.
       METHODS: Didanosine was administered to HIV-positive individuals with
       CD4 levels of 200-500 cells/cmm at a dose of 400 mg/day (po) for six
       weeks (bid), then 2 mg of lentinan iv was added per week for 24-80
       weeks. A control group (20%) received ddI only. About 70 patients have
       been enrolled to date out of a target of 100 patients. Laboratory
       parameters measured were CD4, p24 antigen, chemistry, hematology and
       T-cell panels. RESULTS: The combination was well tolerated and no
       unexpected side effects were observed. Patients generally had improved
       CD4 levels and a reduction in p24 antigen, although the study is still
       blinded. CONCLUSION: Because of the refractory nature of HIV disease it
       is recommended that the above combination of ddI and lentinan be
       supplemented with interleukin-2 and/or curdlan sulfate.
 DE    Adjuvants, Immunologic/*THERAPEUTIC USE  Combined Modality Therapy
       Comparative Study  Didanosine/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       Glucans/ADMINISTRATION & DOSAGE/THERAPEUTIC USE  Human  HIV
       Infections/DRUG THERAPY/*THERAPY  Interleukin-2/ADMINISTRATION &
       DOSAGE/THERAPEUTIC USE  Lentinan/ADMINISTRATION & DOSAGE/*THERAPEUTIC
       USE  Safety  Treatment Outcome  CLINICAL TRIAL  CLINICAL TRIAL, PHASE II
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).